BioWorld

Nov. 17, 2005

Roche Pays Gilead $62.5M To Settle Tamiflu Dispute

To more quickly "address [the] global public health need" of a vaccine against the avian flu, Gilead Sciences Inc. and F. Hoffmann-La Roche Ltd. are ending their dispute over Tamiflu, and $62.5 million is changing hands. (BioWorld Today) Read More

American BioScience Licenses Japanese Rights To Abraxane

Human Channelopathy Project Tackling Epilepsy's Complexity

OncoMethylome Teaming Up With Schering-Plough

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...